Open Nav

 IPCC-Fall 2018 Program Agenda
*As of September 27, 2018

All sessions will take place at the Conrad Indianapolis, in the Vienna Ballroom, South, unless otherwise noted.

Wednesday, November 14, 2018

Registration Open
12:00 pm - 4:30 pm

Opening Session: Cousins Once Removed - What Can Medical Biotechnology Learn from Patent Litigation in Industrial and Agricultural Biotech?
2:00 pm – 3:30 pm

Sponsored by: O'Melveny & Meyers LLP

Moderator: Lisa Pensabene, Partner, O’Melveny & Meyers LLP


  • Dan O’Boyle, Counsel, O’Melveny & Meyers LLP
  • More speakers to be announced

Refreshment Break
3:30 pm – 3:45 pm
Sponsored by: 
Marshall Gerstein & Borun LLP

Education Session 1: Obviousness-Type Double Patenting – Where Are We, and Is It Time for a Legislative Clarification?  
3:45 pm – 5:00 pm
Sponsored by: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Obviousness-type double patenting was created to fill a gap in the patent statute, but it has moved beyond that narrow purpose and has threatened otherwise valid and unobvious patents. This panel will discuss the recent case law of the Federal Circuit, strategies to take during prosecution to reduce risk, and legislative efforts to address this problem.   

Moderator: Howard W. Levine, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP


  • Robert Armitage, Former General Counsel, Eli Lilly and Company
  • Eyal Barash, Chief Intellectual Property Counsel, Endocyte, Inc
  • Alissa Lipton, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Welcome Reception at Skyline Club
5:30 pm – 7:30 pm
Skyline Club
1 American Square, 36th Floor (.3 miles, 5 minute walk from Conrad Indianapolis)

Sponsored by: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP


Thursday, November 15, 2018

IPCC Business Meeting & Breakfast
*Open to IP Counsels Committee company members only
8:30 am – 10:15 am

Breakfast Available for all IPCC Attendees
8:30 am – 10:30 am

Education Session 2: Raising the Stakes in Patent Cases
10:30 am – 11:45 am
Sponsored by: Choate Hall & Stewart LLP

From on-sale bar to sovereign immunity, this panel will discuss several recent important cases and their impact on the life sciences community. Specifically, we will review key Supreme Court and Federal Circuit cases addressing challenges associated with enforcement and damages, including: on-sale bar under AIA (Helsinn v. Teva), implications of sovereign immunity in IPR proceedings (U. Minnesota v. LSI), questions around standing to appeal a PTAB decision (Momenta v. BMS), the latest on induced infringement (GSK v. Teva), and the issues of lost foreign profits and apportionment for patent infringement (WesternGeco v. ION Geophysical Corp. and Power Integrations v. Fairchild Semiconductor).

Moderator: Eric J. Marandett, Partner, Choate Hall & Stewart LLP


  • Kristen C. Buteau, Counsel, Choate, Hall & Stewart
  • Cambria Alpha Cobb, Patent Agent, Momenta Pharmaceuticals
  • Kevin McGough, Vice President, IP Legal, Shire Pharmaceuticals

Lunch Buffet & Keynote featuring Professor Mark D. Janis, Robert A. Lucas Chair and Professor of Law; Director, Center for Intellectual Property Research, Maurer School of Law, Indiana University 
11:45 am – 1:00 pm
Sponsored by: Brinks Gilson & Lione

Education Session 3: Outcomes, Trends, and Practice Changes in the Patent Trial and Appeal Board 
1:00 pm – 2:15 pm
Sponsored by: Fitzpatrick

This panel will discuss current IPR statistics with a focus on biologic and small molecule drug IPRs.  This will include statistics on IPR institution rates overall, for biologics and small molecule drugs, and the impact of Patent Owners submitting declarations with their Preliminary responses.  We will also take a look at whether institution rates are changing after the April Supreme Court decision in SAS Institute.  Further discussion will include statistics relating to serial petitions and varying institution and final written decision outcomes based on claim types challenged.

Moderator: Robert S. Schwartz, PhD, Partner, Fitzpatrick


  • Gonzalo Merino, PhD, Chief Intellectual Property Counsel, Regeneron Pharmaceuticals, Inc.
  • Corrine E. Atton, Associate, Fitzpatrick

Refreshment Break
2:15 pm – 2:30 pm
Sponsored by: 
Marshall Gerstein & Borun LLP

Education Session 4: The Role of CRISPR in Agricultural, Industrial, and Medical Biotechnology – What Every Patent Practitioner Should Know
2:30 pm – 3:45 pm
Sponsored by: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

While CRISPR technology promises technological breakthroughs in genetic manipulation and the associated treatment of disease, it poses challenges to U.S. Patent law. The panel will discuss these challenges and potential ways to address them. 

Moderator: Howard W. Levine, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP


  • Amanda Murphy, Ph.D., Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
  • Murray Spruill, Vice President, Intellectual Property, Benson Hill Biosystems

Networking Happy Hour (at Conrad Indy)
3:45 pm – 5:00 pm
Sponsored by: McNeill Baur

Activity and Dinner Reception at Dallara IndyCar Factory
5:30 pm – 8:30 pm
Sponsored byMcDonnell Boehnen Hulbert & Berghoff LLP

Dallara IndyCar Factory
1201 Main St. (5 miles, 15 minute drive from Conrad Indianapolis)
Get your adrenaline pumping with a variety of interactive exhibits and activities centered around the world’s fastest sport. The Dallara IndyCar Factory is the destination for seasoned racing enthusiasts and newcomers alike. Get in the racing spirit with full size Indycar race simulators and a real time pit stop challenge in the Interactive Hall, before sitting down to dinner among Indy 500 racecars. 

Transportation will be provided to the venue. Details for transportation will be emailed the week prior of the event.

Friday, November 16, 2018

8:00 am – 8:30 am

Education Session 5: “I’ll be Back.” The FDA’s Biosimilars Action Plan, Regulatory Guidances, and Their Impact on IP
8:30 am – 9:45 am
Sponsored by: Fitzpatrick

This panel will discuss the new FDA Biosimilar Action Plan and stakeholders’ responses as well as recent FDA Guidances concerning biologics, biosimilars and interchangeables and their potential impact on IP from R&D and biologic developments into the future.

Moderator: Ha Kung Wong, Partner, Fitzpatrick


  • Jeff Kopacz, Senior Director, Senior Patent Counsel, Alnylam Pharmaceuticals
  • Claire Vasios, Vice President, Intellectual Property, Alkermes, Inc

Refreshment Break
9:45 am – 10:00 am
Sponsored by: 
Marshall Gerstein & Borun LLP

Education Session 6: Trade Secrets in an Evolving Landscape: Practice Pointers for Biotech Patent Practitioners
10:00 am – 11:15 am
Sponsored by: Choate Hall & Stewart LLP

This panel will discuss recent happenings in trade secret law, including a national uptick in trade secret litigation, important US cases from the past year, and international perspectives on trade secret litigation.

Moderator: Anita Spieth, Counsel, Choate Hall & Stewart LLP


  • Steve Bossone, Vice President, Intellectual Property, Alnylam Pharmaceuticals
  • Kerry Flynn, VP, Chief IP Counsel, Vertex Pharmaceuticals
  • David Wilson, Partner, Carpmaels & Ransford LLP

Program Adjourns
11:15 am


>>View the 2018 IPCC-Spring Program Agenda to learn more about our session topics and featured speakers!